Clopidogrel-induced hepatotoxicity after percutaneous coronary stenting

TN Chau, KF Yim, NS Mok, WK Chan, VKS Leung, MF Leung, ST Lai
Department of Medicine and Geriatrics, United Christian Hospital, Kwun Tong, Hong Kong


Clopidogrel, an adenosine diphosphate receptor blocker, is widely used as an adjunctive antiplatelet therapy in acute coronary syndrome and percutaneous coronary stenting. The occurrence of hepatotoxicity is rare. We describe the occurrence of symptomatic liver disease in a 74-year-old man 5 weeks following commencement of therapy with clopidogrel. The reported cases of clopidogrel-induced hepatotoxicity are reviewed and the clinical significance of this event are discussed.

Hong Kong Med J 2005;11:414-6

Key words: Adverse effects; Clopidogrel; Drug toxicity; Hepatitis